Cardiac Procedures for Atrial Fibrillation

Patient Selection

• The Watchman device is indicated for patients with non-valvular atrial fibrillation who have contraindications to long-term oral anticoagulation, or an appropriate rationale to seek a non-pharmacologic alternative to anticoagulation, as recommended by the American College of Cardiology and the FDA 1
• Patients must have contraindications to long-term oral anticoagulation, such as a history of major bleeding events, high bleeding risk (HAS-BLED score ≥3), inability to maintain stable INR on warfarin, or poor medication adherence or tolerance, with a Class IIb recommendation and Level B-NR evidence 1, 2, 3, 4
• The American Heart Association/American College of Cardiology/Heart Rhythm Society recommends the Watchman device for patients with non-valvular atrial fibrillation and a CHA₂DS₂-VASc score ≥2 for men or ≥3 for women, who have a rationale for seeking a non-pharmacologic alternative to oral anticoagulation, with a strength of evidence classified as Class IIb (may be considered) with Level B-NR evidence 5, 2, 3, 6

Procedure-Related Complications

• Pericardial effusion occurs in approximately 0.68-7.1% of Watchman procedures, and is considered a serious cause requiring immediate evaluation, as per the guidelines from Nature Reviews Cardiology 7
• Device-related thrombus occurs in approximately 2-5% of patients, with risk factors including non-paroxysmal atrial fibrillation, renal insufficiency, history of TIA or stroke, deep device implantation, left ventricular dysfunction, and incomplete LAA sealing, as per the guidelines from Nature Reviews Cardiology 7
• Peridevice leak is relatively common, occurring in 26-57% of patients depending on imaging technique, and is associated with increased risk of thromboembolism and potential chest discomfort, according to Nature Reviews Cardiology 7
• Key complications to be aware of include pericardial effusion (4.4-7.1% of cases), device embolization, procedure-related ischemic stroke, and device-related thrombus formation, as recommended by the FDA and professional societies, including the American College of Cardiology 2, 3, 4

Post-Procedure Management

• The American College of Cardiology recommends immediate assessment of vital signs, ECG, and focused cardiac examination for signs of tamponade in patients with chest pain after Watchman device placement, with high-risk patients requiring immediate echocardiogram (preferably TEE) to assess for pericardial effusion, device position and stability, and evidence of thrombus 7
• Moderate-risk patients should undergo echocardiogram within 24 hours, while low-risk patients can have outpatient echocardiogram, as per the guidelines from Nature Reviews Cardiology 7
• Patients should be monitored with TEE at scheduled intervals (45 days, 6 months, and sometimes 12 months) to ensure proper device function and absence of complications, as recommended by the American College of Cardiology and the European Society of Cardiology 8, 2, 9, 10
• The following medication regimen is recommended:

2, 5, 9, 4

Treatment of Complications

• Pericardial effusion requires urgent pericardiocentesis if hemodynamically significant, as recommended by the American Heart Association
• Device-related thrombus requires anticoagulation according to guidelines from the American College of Cardiology
• Device embolization requires surgical or percutaneous retrieval, as stated by the Society for Cardiovascular Angiography and Interventions
• Musculoskeletal pain can be managed conservatively with analgesics, as recommended by the American College of Radiology 11
• Immediate anticoagulation is strongly recommended for patients with atrial thrombus after Watchman procedure to prevent stroke and systemic embolization, according to the European Society of Cardiology 12